Skip to main content
SpringerLink
Log in

Antiemetic Prophylaxis of Radiotherapy-Induced Nausea and Vomiting

  • Chapter
  • First Online:
Prevention of Nausea and Vomiting in Cancer Patients

  • 767 Accesses

Abstract

Although radiotherpy-induced nausea and vomiting (RINV) is often less severe than chemotherapy-induced nausea and vomiting (CINV), these side effects can be quite distressing. RINV is still often underestimated by radiation oncologists. However, as many as 50–80 % of patients undergoing radiotherapy will experience these side effects, depending on the site of irradiation.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 49.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Feyer P, Maranzano M, Molassiotis A, et al. Radiotherapy-induced nausea and vomiting (RINV): MASCC/ESMO Guideline for Antiemetics in Radiotherapy: update 2009. Support Care Cancer. 2011(suppl 1):S5-S14.

    Google Scholar 

  2. Roila F, Herrstedt J, Aapro M, et al. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference Ann Oncol. 2010:21(suppl 5):v232–v243.

    Google Scholar 

  3. Feyer P, Seegenschmiedt MH, Steingraeber M. Granisetron in the control of radiotherapyinduced nausea and vomiting: a comparison with other antiemetic therapies. Support Care Cancer. 2005;13:671-678.

    Google Scholar 

  4. Aass N, Hatun DE, Thoresen M, Fossa SD. Prophylactic use of tropisetron or metoclopramide during adjuvant abdominal radiotherapy of seminoma stage I: a randomised, open trial in 23 patients. Radiother Oncol. 1997;45:125-128.

    Google Scholar 

  5. Bey P, Wilkinson PM, Resbeut M, et al. A double-blind, placebo-controlled trial of i.v. dolasetron mesilate in the prevention of radiotherapy-induced nausea and vomiting in cancer patients. Support Care Cancer. 1996;4:378-383.

    Google Scholar 

  6. Franzen L, Nyman J, Hagberg H, et al. A randomised placebo controlled study with ondansetron in patients undergoing fractionated radiotherapy. Ann Oncol. 1996;7:587-592.

    Google Scholar 

  7. Lanciano R, Sherman DM, Michalski J, et al. The efficacy and safety of once-daily Kytril (granisetron hydrochloride) tablets in the prophylaxis of nausea and emesis following fractionated upper abdominal radiotherapy. Cancer Invest. 2001;19:763-772.

    Google Scholar 

  8. Priestman TJ, Roberts JT, Lucraft H, et al. Results of a randomised, double-blind comparative study of ondansetron and metoclopramide in the prevention of nausea and vomiting following high-dose upper abdominal irradiation. Clin Oncol (R Coll Radiol). 1990;2:71-75.

    Google Scholar 

  9. Priestman TJ, Roberts JT, Upadhyaya BK. A prospective randomised double-blind trial comparing ondansetron versus prochlorperazine for the prevention of nausea and vomiting in patients undergoing fractionated radiotherapy. Clin Oncol (R Coll Radiol). 1993;5:358-363.

    Google Scholar 

  10. Wong RK, Paul N, Ding K, et al. 5-hydroxytryptamine-3 receptor antagonist with or without shortcourse dexamethasone in the prophylaxis of radiation induced emesis: a placebocontrolled randomised trial of the National Cancer Institute of Canada Clinical Trials Group (SC19). J Clin Oncol. 2006;24:3458-3464.

    Google Scholar 

  11. Mystakidou K, Katsouda E, Linou A, et al. Prophylactic tropisetron versus rescue tropisetron in fractionated radiotherapy to moderate or high emetogenic areas: a prospective randomized open label study in cancer patients. Med Oncol. 2006;23:251-262.

    Google Scholar 

  12. Prentice HG, Cunningham S, Gandhi L, et al. Granisetron in the prevention of irradiationinduced emesis. Bone Marrow Transplant. 1995;15:445-458.

    Google Scholar 

  13. Spitzer TR, Bryson JC, Cirenza E, et al. Randomised double-blind, placebo-controlled evaluation of oral ondansetron in the prevention of nausea and vomiting associated with fractionated total body irradiation. J Clin Oncol. 1994;12:2432-2438.

    Google Scholar 

  14. Spitzer TR, Friedman CJ, Bushnell W, et al. Double-blind, randomised, parallel-group study on the efficacy and safety of oral granisetron and oral ondansetron in the prophylaxis of nausea and vomiting in patients receiving hyperfractionated total body irradiation. Bone Marrow Transplant. 2000;26:203-210.

    Google Scholar 

  15. Sykes AJ, Kiltie AE, Stewart AL. Ondansetron versus a chlorpromazine and dexamethasone combination for the prevention of nausea and vomiting: a prospective, randomised study to assess efficacy, cost effectiveness and quality of life following single-fraction radiotherapy. Support Care Cancer. 1997;5:500-503.

    Google Scholar 

  16. Tiley C, Powles R, Catalano J, et al. Results of a double blind placebo controlled study of ondansetron as an antiemetic during total body irradiation in patients undergoing bone marrow transplantation. Leuk Lymphoma. 1992;7:317-321.

    Google Scholar 

  17. Huang X, Guo N, Fan Y. [Ondansetron in the prophylaxis of acute emesis induced by suprahigh single dose total body irradiation (TBI)]. Zhonghua Zhong Liu Za Zhi. 1995;17:64-66.

    Google Scholar 

  18. Goodin S, Cunningham R. 5-HT(3)-receptor antagonists for the treatment of nausea and vomiting: a reappraisal of their side-effect profile. Oncologist. 2002;7:424-436.

    Google Scholar 

  19. Jordan K, Schmoll HJ, Aapro MS. Comparative activity of antiemetic drugs. Crit Rev Oncol Hematol. 2007;61:162-175.

    Google Scholar 

  20. Feyer PC, Stewart AL, Titlbach OJ. Aetiology and prevention of emesis induced by radiotherapy. Support Care Cancer. 1998;6:253-260.

    Google Scholar 

  21. Belli C, Dahl T, Herrstedt J. Palonosetron plus prednisolone in patients receiving fractionated radiotherapy plus weekly cisplatin. Support Care Cancer. 2008;16:01-004.

    Google Scholar 

  22. Dimitrijevic J, Medic-Milijic N. Prevention of nausea and vomiting induced by chemotherapy followed by combined chemo/radiotherapy in head and neck cancer patients. Support Care Cancer. 2009;17:02-009.

    Google Scholar 

  23. Kirkbride P, Bezjak A, Pater J, et al. Dexamethasone for the prophylaxis of radiation-induced emesis: a National Cancer Institute of Canada Clinical Trials Group phase III study. J Clin Oncol. 2000;18:1960-1966.

    Google Scholar 

  24. Feyer P, Maranzano E, Molassiotis A, et al. Radiotherapy-induced nausea and vomiting (RINV): antiemetic guidelines. Support Care Cancer. 2005;13:122-128.

    Google Scholar 

  25. Kris MG, Hesketh PJ, Somerfield MR, et al. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol. 2006;24:2932-2947.

    Google Scholar 

  26. Jordan K, Schmoll HJ, Aapro MS. Comparative activity of antiemetic drugs. Crit Rev Oncol Hematol. 2007; 61:162-175.

    Google Scholar 

  27. Yamamoto K, Nohara K, Furuya T, Yamatodani A. Ondansetron, dexamethasone and an NK 1 antagonist block radiation sickness in mice. Pharmacol Biochem Behav. 2005;82:24-29.

    Google Scholar 

  28. LeBourgeois JP, McKenna CJ, Coster B, et al. Efficacy of an ondansetron orally disintegrating tablet: a novel oral formulation of this 5-HT(3) receptor antagonist in the treatment of fractionated radiotherapy-induced nausea and emesis. Emesis Study Group for the Ondansetron Orally Disintegrating Tablet in Radiotherapy Treatment. Clin Oncol (R Coll Radiol). 1999;11:340-347.

    Google Scholar 

  29. Maranzano E, Feyer P, Molassiotis A, et al. Evidence-based recommendations for the use of antiemetics in radiotherapy. Radiother Oncol. 2005;76:227-233.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Multidisciplinary Oncology Institute Clinique de Genolier, Genolier, Vaud, Switzerland

    Matti Aapro

  2. Department of Oncology/Haematology, Martin Luther University Hospital Clinic for Internal Medicine, Halle, Germany

    Karin Jordan

  3. Radioonkologie und Nuklearmedizin, Vivantes Klinikum Neukölln Klinik für Strahlentherapie, Berlin, Germany

    Petra Feye

Authors
  1. Matti Aapro
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Karin Jordan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Petra Feye
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Petra Feye .

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Healthcare

About this chapter

Cite this chapter

Aapro, M., Jordan, K., Feye, P. (2013). Antiemetic Prophylaxis of Radiotherapy-Induced Nausea and Vomiting. In: Prevention of Nausea and Vomiting in Cancer Patients. Springer Healthcare, Tarporley. https://doi.org/10.1007/978-1-907673-58-0_7

Download citation

  • DOI: https://doi.org/10.1007/978-1-907673-58-0_7

  • Published:

  • Publisher Name: Springer Healthcare, Tarporley

  • Print ISBN: 978-1-908517-87-6

  • Online ISBN: 978-1-907673-58-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation